Burning Rock Biotech (NASDAQ:BNR) Releases Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) posted its quarterly earnings data on Tuesday. The company reported ($1.08) earnings per share (EPS) for the quarter, Zacks reports. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $4.82 on Wednesday. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $8.99. The stock has a market capitalization of $49.38 million, a price-to-earnings ratio of -1.61 and a beta of 0.55. The business has a 50-day moving average of $6.28 and a 200-day moving average of $5.28.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.